<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "axitinib tab>
<dose><value>2</value>
<value>3</value>
<value>5</value>
<value>7</value>
<value>10</value>
</dose><route><value>PO</value>
</route><form><value>tab</value>
</form><drug><value>axitinib tab</value>
</drug><strength><value>1 mg </value>
<value>5 mg</value>
</strength><frequency><value>BID</value>
</frequency><instruction><value></value>
</instruction><volume><value></value>
</volume><units><value>mg</value>
</units><additionalnotes><value>Child-Pugh class B: starting dose should be decreased by approximately half in moderate impairment. If patients tolerate starting dose and experience no adverse reaction greater than grade 2 for two consecutive weeks, are normotensive and are not receiving antihypertensives, dose may be increased from 5mg BID to 7 mg BID. Subsequently, using the same criteria, patients tolerating 7 mg BID may have dose increased to a maximum of 10 mg BID. </value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6401</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6402</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>